Madrigal Pharmaceuticals stock hits all-time high at 423.4 USD

Madrigal Pharmaceuticals Inc. (market cap: $9.42B) has reached a significant milestone as its stock hit an all-time high of 423.4 USD. According to InvestingPro data, the stock is currently trading near its 52-week high, with technical indicators suggesting overbought conditions. This achievement underscores a robust performance, with the company’s stock experiencing a remarkable 65.1% increase over the past year. The surge reflects growing investor confidence and interest in Madrigal Pharmaceuticals, which has been gaining traction in the market. Notably, the stock’s beta of -1.03 indicates it often moves contrary to broader market trends, potentially offering portfolio diversification benefits. This all-time high suggests a positive outlook for the company’s future, as it continues to capture attention with its strategic initiatives and developments. InvestingPro analysis suggests the stock is slightly undervalued at current levels, with 14 additional exclusive ProTips available to subscribers, along with a comprehensive Pro Research Report offering deep-dive analysis of what really matters for smarter investment decisions.

In other recent news, Madrigal Pharmaceuticals has received significant attention following the European Union’s approval of its MASH treatment, Rezdiffra. This approval marks Rezdiffra as the first medication authorized for treating noncirrhotic MASH with moderate to advanced liver fibrosis in the EU. The company plans to launch the drug in Germany next quarter, targeting approximately 370,000 patients under the care of liver specialists. Following this development, TD Cowen raised its price target for Madrigal Pharmaceuticals to $554, maintaining a Buy rating, while Citizens JMP increased its target to $485 with a Market Outperform rating.

Cantor Fitzgerald, however, maintained a Neutral rating on the stock, focusing on the company’s new weight-based dosing patent for Rezdiffra, which has become a topic of interest among investors. This patent, set to expire in February 2045, was discussed with an intellectual property expert to assess its strength. These recent developments have positioned Madrigal Pharmaceuticals at the forefront of MASH treatment in the European market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.